Loading…
Repligen Corporation is projected to rise to $187.47 by 2027, a +30% move from its current price of $144.02. RGEN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $140.26 | $144.11 | $148.06 | +0.06% |
| Jul 13 | $138.78 | $144.20 | $149.83 | +0.13% |
| Jul 14 | $137.68 | $144.29 | $151.22 | +0.19% |
| Jul 15 | $136.77 | $144.38 | $152.42 | +0.25% |
| Jul 16 | $135.98 | $144.47 | $153.49 | +0.32% |
| Jul 17 | $135.29 | $144.57 | $154.48 | +0.38% |
| Jul 18 | $134.66 | $144.66 | $155.40 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $134.66 | $144.66 | $155.40 | +0.45% |
| Week 2 | $131.30 | $145.30 | $160.80 | +0.89% |
| Week 3 | $128.92 | $145.95 | $165.23 | +1.34% |
| Week 4 | $127.03 | $146.60 | $169.19 | +1.80% |
| Week 5 | $125.46 | $147.25 | $172.84 | +2.25% |
| Week 6 | $124.10 | $147.91 | $176.29 | +2.71% |
| Week 7 | $122.92 | $148.57 | $179.58 | +3.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Its portfolio includes hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Repligen Corporation (RGEN) is currently priced at $145.23, with a market cap of $8.19B, and ranks 1034 by market capitalization.
The 30-day technical picture shows bullish sentiment with RSI14 at 70, and the stock trading above SMA50 of $122.30 but below SMA200 of $138.47.
Near-term support stands at $102.87 and resistance at $145.23; the 30-day range runs from $119.40 to $176.65. The long-range forecast projects an upswing, with 2026 avg $145.23, 2027 avg $189.68, 2028 avg $217.26, 2029 avg $217.15, 2030 avg $242.08, 2040 avg $659.72, and 2050 avg $1,257.02, with a max of $2,400.59.
A major floor 28.6% below — a decisive break under it would weaken the trend.
The nearest floor, 15.9% below — buyers have tended to step in here.
Price is pressing into resistance (2.1% away) — a breakout level to watch.
A major ceiling 13.4% above — clearing it would confirm fresh momentum.
Key RGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $141.38 | Buy | $141.95 | Buy |
| MA 10 | $140.87 | Buy | $140.27 | Buy |
| MA 20 | $136.87 | Buy | $136.67 | Buy |
| MA 50 | $125.54 | Buy | $130.38 | Buy |
| MA 100 | $124.17 | Buy | $130.08 | Buy |
| MA 200 | $139.52 | Buy | $133.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.95 | Neutral |
| Stoch RSI (14) | 50.85 | Neutral |
| CCI (20) | 97.58 | Neutral |
| Williams %R (14) | -13.42 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 14.14 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 86.58 | Sell |
| TRIX (15) | 0.56 | Buy |
| Awesome (5,34) | 10.73 | Buy |
| Ultimate (7,14,28) | 67.43 | Neutral |
| Momentum (10) | -0.99 | Sell |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 142.04 | Buy |
| ADX (14) | 20.63 | Buy |
| ATR (14) | 3.14 | Info |
The 30-day picture is bullish, with RSI14 at 70, and the stock trades relative to key moving averages: SMA50 is $122.30 and SMA200 is $138.47.
Current price sits near the resistance level at $145.23, while a support level is noted at $102.87. The 30-day range spans from $119.40 to $176.65, indicating notable near-term volatility and potential for movement within that band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $102.87 | $144.02 | $205.18 | 0% | Neutral | |
| $149.35 | $187.47 | $248.89 | +30% | Bullish | |
| $169.90 | $219.23 | $301.93 | +52% | Bullish | |
| $171.56 | $226.50 | $321.03 | +57% | Bullish | |
| $187.20 | $252.20 | $366.19 | +75% | Bullish | |
| $214.08 | $293.78 | $435.65 | +104% | Bullish | |
| $250.89 | $350.24 | $529.30 | +143% | Bullish | |
| $294.41 | $417.67 | $642.10 | +190% | Bullish | |
| $302.22 | $435.34 | $679.91 | +202% | Bullish | |
| $299.58 | $437.89 | $693.97 | +204% | Bullish | |
| $471.20 | $735.94 | $1,240.14 | +411% | Bullish | |
| $828.33 | $1,449.94 | $2,671.91 | +907% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $102.87 | $144.02 | $177.67 | +0.00% |
| August 2026 | $128.61 | $151.79 | $183.96 | +5.40% |
| September 2026 | $128.41 | $152.61 | $186.99 | +0.54% |
| October 2026 | $132.99 | $159.00 | $196.63 | +4.19% |
| November 2026 | $136.91 | $164.50 | $205.01 | +3.46% |
| December 2026 | $135.41 | $163.47 | $205.18 | -0.63% |
Click any year to see its month-by-month RGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The RGEN price prediction for 2026 points to an average of $144.02 (low $102.87, high $205.18) — a potential gain of 0% on today's $144.02. A consolidation phase looks the most probable path here.
In 2027, RGEN is projected to trade between $149.35 and $248.89, averaging $187.47 — a potential gain of +30% from today's $144.02. That is up +30% on the projected 2026 average. Momentum favours further upside here.
Repligen Corporation's 2028 outlook centres on $219.23, within a $169.90 to $301.93 range. That is up +17% on the projected 2027 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, RGEN could reach as high as $321.03, with a base case around $226.50 and support toward $171.56 — roughly +57% from $144.02. Momentum favours further upside here.
Expect RGEN to range from $187.20 to $366.19 through 2030. The $252.20 average target implies a +75% move from current prices. That is up +11% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The RGEN price prediction for 2031 points to an average of $293.78 (low $214.08, high $435.65) — a potential gain of +104% on today's $144.02. Momentum favours further upside here.
In 2032, RGEN is projected to trade between $250.89 and $529.30, averaging $350.24 — a potential gain of +143% from today's $144.02. That is up +19% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Repligen Corporation's 2033 outlook centres on $417.67, within a $294.41 to $642.10 range. That is up +19% on the projected 2032 average. That marks a +190% change versus current levels. Momentum favours further upside here.
By 2034, RGEN could reach as high as $679.91, with a base case around $435.34 and support toward $302.22 — roughly +202% from $144.02. Buyers look set to stay in control over this stretch.
Expect RGEN to range from $299.58 to $693.97 through 2035. The $437.89 average target implies a +204% move from current prices. That is up +1% on the projected 2034 average. Momentum favours further upside here.
The RGEN price prediction for 2040 points to an average of $735.94 (low $471.20, high $1,240.14) — a potential gain of +411% on today's $144.02. Buyers look set to stay in control over this stretch.
In 2050, RGEN is projected to trade between $828.33 and $2,671.91, averaging $1,449.94 — a potential gain of +907% from today's $144.02. That is up +97% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RGEN today (≈ 6.943721 RGEN) could be worth
$10,067.98
+$9,067.98 (+907%) by 2050 · US Dollar
Based on the average projected RGEN price of $1,449.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RGENwould be worth at today's price.
$1,000 invested in RGEN on Jul 10, 2025 (≈ 7.462687 RGEN) would be worth
$1,074.74
+$74.74 (+7.5%) today · 1.07× · US Dollar
Based on a RGEN entry price of $134 vs. today's $144.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $142.4 | $1,011.34 | +1.1% |
| 1 month ago | $130.76 | $1,101.37 | +10.1% |
| 3 months ago | $120.1 | $1,199.13 | +19.9% |
| 6 months ago | $168.4 | $855.2 | -14.5% |
| 1 year ago | $134 | $1,074.74 | +7.5% |
| All time (5.0y) ago | $204.31 | $704.88 | -29.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RGEN forecast.
Our base-case forecast reaches $290.00 around 2031.
Implied market cap at $290.00: $16.36B
The multi-year forecast shows bullish sentiment across the 2027–2050 horizon. In 2027 the avg price is $189.68 with ROI 30.6; in 2028 the avg is $217.26 with ROI 49.6; in 2029 the avg is $217.15 with ROI 49.5; in 2030 the avg is $242.08 with ROI 66.7.
Further out, 2031 the avg is $276.92 with ROI 90.7; 2032 the avg is $328.07 with ROI 125.9; 2033 the avg is $398.48 with ROI 174.4; 2034 the avg is $401.74 with ROI 176.6; 2035 the avg is $395.05 with ROI 172. The horizon then extends to 2040 with avg $659.72 and ROI 354.3, and to 2050 with avg $1,257.02 and ROI 765.5.
Tap a question to reveal the answer.
2030 min: "$176.53"; avg: "$242.08"; max: "$358.72"; ROI 66.7; sentiment BULLISH.
The forecast shows a bullish path with rising averages and ROIs from 2027 onward, including 2027 ROI 30.6 and 2050 ROI 765.5, with the 2030 average at $242.08. These are estimates and not guarantees.
Yes, the 2050 max is "$2,400.59", and the 2050 average is "$1,257.02", which implies the possibility of surpassing $1,000 according to the projected path, though it is not guaranteed.
Current price is "$145.23" and market cap is "$8.19B".
2035 avg is "$395.05" with max "$642.78" and ROI 172; sentiment is BULLISH.
Repligen Corporation Community Discussion
0Share your Repligen Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.